drugset / Trial / NCT01232946
Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake
RandomizedParallel-groupOpen-labelOther
Summary
27 Type 2 diabetic subjects (HbA1c 7.5 - 9.5%) currently treated with diet and exercise alone or with oral antidiabetic agents will be randomly assigned to one of three treatment groups: insulin detemir, liraglutide, or liraglutide plus detemir (9 subjects per group), on a background of metformin 2000 mg per day. After 3 months' treatment, PET measurements of myocardial fuel selection will take place, under fasting conditions in the morning following that day's treatment injection(s).
Timeline
- Start
- 2012-01
- Primary completion
- 2017-09-08
- Completion
- 2017-09-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liraglutide | Peptide | 1.8 mg | Subcutaneous |
| Subject | insulin detemir | Protein / enzyme biologic | 5 iu | Subcutaneous |